Fool - Investing News
06 Jun 2026, 18:19 UTC · 15w ago
Verdict
Headline takes no side. We score TWST +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 84% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Twist Bioscience raised its 2026 full-year sales growth guidance to 17% to 19% year over year.
More positive than 92% of claims this week
Twist Bioscience reported fiscal second quarter revenue growth of 19% year over year to $110.7 million.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 76% of claims this week
Chief Legal Officer Dennis Cho sold 14,205 shares of TWST for approximately $991,000 on May 29, 2026.
So whatWhile insider selling can be a red flag, this specific trade was prearranged via a Rule 10b5-1 plan and represents a small fraction of his total holdings.
More negative than 66% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
The company reported strong revenue growth, raised full-year guidance, and is described as having excellent business performance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+139.5%
Price agrees with the score
$165.81 vs $69.22 close before publication (Jun 5) · not market-adjusted
TWST chart →